Stephen Hanauer to Risk Assessment
This is a "connection" page, showing publications Stephen Hanauer has written about Risk Assessment.
Connection Strength
0.836
-
Initial Assessment of Post-traumatic Stress in a US Cohort of Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2019 08 20; 25(9):1577-1585.
Score: 0.393
-
Complications of peristomal recurrence of Crohn's disease: a case report and a review of literature. J Wound Ostomy Continence Nurs. 2012 May-Jun; 39(3):297-301.
Score: 0.059
-
Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011 Apr; 106(4):685-98.
Score: 0.055
-
Devolving therapeutic pyramids. Nat Rev Gastroenterol Hepatol. 2010 Mar; 7(3):119-20.
Score: 0.051
-
Modifying risk factors: do the means justify the ends? Nat Clin Pract Gastroenterol Hepatol. 2008 Sep; 5(9):475.
Score: 0.046
-
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007 Sep; 56(9):1181-3.
Score: 0.043
-
Where do our priorities lie? Nat Clin Pract Gastroenterol Hepatol. 2007 Jul; 4(7):353.
Score: 0.042
-
Moving ahead or falling behind? Nat Clin Pract Gastroenterol Hepatol. 2007 Jun; 4(6):295.
Score: 0.042
-
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004 Jul; 2(7):542-53.
Score: 0.034
-
The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(2):81-92.
Score: 0.031
-
The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998 Oct; 93(10):1867-72.
Score: 0.023
-
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520.
Score: 0.012
-
International forum on ulcerative colitis. Risk selection aspects of ulcerative colitis. J Insur Med. 1995; 27(2):167-80.
Score: 0.004